TY - JOUR
T1 - A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
AU - Kalogera, Eleftheria
AU - Nevala, Wendy K.
AU - Finnes, Heidi D.
AU - Suman, Vera J.
AU - Schimke, Jill M.
AU - Strand, Carrie A.
AU - Kottschade, Lisa A.
AU - Kudgus, Rachel A.
AU - Buhrow, Sarah A.
AU - Becher, Laura R.
AU - Geng, Liyi
AU - Glaser, Gretchen E.
AU - Grudem, Megan E.
AU - Jatoi, Aminah
AU - Klampe, Carolyn M.
AU - Kumar, Amanika
AU - Langstraat, Carrie L.
AU - McWilliams, Robert R.
AU - Wahner Hendrickson, Andrea E.
AU - Weroha, S. John
AU - Yan, Yiyi
AU - Reid, Joel M.
AU - Markovic, Svetomir N.
AU - Block, Matthew S.
N1 - Publisher Copyright:
©2024 The Authors; Published by the American Association for Cancer Research.
PY - 2024/6/15
Y1 - 2024/6/15
N2 - Purpose: AB160 is a 160-nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles noncovalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared with sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers. Patients and Methods: A 3+3 phase I trial was conducted with three potential dose levels in patients with previously treated endometrial, cervical, and platinum-resistant ovarian cancer to ascertain the recommended phase II dose (RP2D). AB160 was administered intravenously on days 1, 8, and 15 of a 28-day cycle (ABX 75–175 mg/m2, BEV 30–70 mg/m2). Pharmacokinetic analyses were performed. Results: No dose-limiting toxicities (DLT) were seen among the three dose levels tested. Grade 3/4 toxicities included neutropenia, thromboembolic events, and leukopenia. DL2 (ABX 150 mg/m2, BEV 60 mg/m2) was chosen as the RP2D. Seven of the 19 patients with measurable disease (36.8%) had confirmed partial responses (95% confidence interval, 16.3%–61.6%). Pharmacokinetic analyses demonstrated that AB160 allowed 50% higher paclitaxel dosing and that paclitaxel clearance mirrored that of therapeutic antibodies. Conclusions: The safety profile and clinical activity of AB160 supports further clinical testing in patients with gynecologic cancers; the RP2D is DL2 (ABX 150 mg/m2, BEV 60 mg/m2).
AB - Purpose: AB160 is a 160-nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles noncovalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared with sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers. Patients and Methods: A 3+3 phase I trial was conducted with three potential dose levels in patients with previously treated endometrial, cervical, and platinum-resistant ovarian cancer to ascertain the recommended phase II dose (RP2D). AB160 was administered intravenously on days 1, 8, and 15 of a 28-day cycle (ABX 75–175 mg/m2, BEV 30–70 mg/m2). Pharmacokinetic analyses were performed. Results: No dose-limiting toxicities (DLT) were seen among the three dose levels tested. Grade 3/4 toxicities included neutropenia, thromboembolic events, and leukopenia. DL2 (ABX 150 mg/m2, BEV 60 mg/m2) was chosen as the RP2D. Seven of the 19 patients with measurable disease (36.8%) had confirmed partial responses (95% confidence interval, 16.3%–61.6%). Pharmacokinetic analyses demonstrated that AB160 allowed 50% higher paclitaxel dosing and that paclitaxel clearance mirrored that of therapeutic antibodies. Conclusions: The safety profile and clinical activity of AB160 supports further clinical testing in patients with gynecologic cancers; the RP2D is DL2 (ABX 150 mg/m2, BEV 60 mg/m2).
UR - http://www.scopus.com/inward/record.url?scp=85196230778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85196230778&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-23-3196
DO - 10.1158/1078-0432.CCR-23-3196
M3 - Article
C2 - 38530846
AN - SCOPUS:85196230778
SN - 1078-0432
VL - 30
SP - 2623
EP - 2635
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -